In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma
Some new medicines reprogramme immune cells inside the body with an injection, skipping the factory entirely. Test whether that makes CAR-T affordable and available in ordinary hospitals.
In vivo CAR-T uses targeted lipid nanoparticles or engineered lentiviral vectors to deliver the CAR gene to T cells inside the patient (programmes from Interius, Umoja, Orna, Capstan and others entered the clinic in 2024-25). This idea is not about which antigen to hit but about manufacturing and delivery economics: a frozen vial produced in batches of thousands, administered in a community hospital with no apheresis, no bridging chemotherapy and possibly no lymphodepletion. A companion idea in this corpus covers solid-tumour antigens.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaIn vivo CAR-T manufactured and priced like a generic biologic
Shares Interius BioTherapeutics, Umoja Biopharma, In vivo CAR-T against solid-tumour antigens, Orna Therapeutics (Eli Lilly).
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- CompanySana Biotechnology
Shares In vivo CAR-T, CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma.
- CompanyCaribou Biosciences
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares CD19, Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- IdeaCollect and freeze T cells at diagnosis for high-risk patients, before chemotherapy
Shares Manufacturing cost and time for living and radioactive medicines, Diffuse large B-cell lymphoma, CAR-T cell therapy.